{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"8.38","upperLimit":"148.81","value":"26"},{"groupId":"OG001","lowerLimit":"14","upperLimit":"61.6","value":"30.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"15"}],"units":"Participants"}],"description":"Numbers of circulating CD34+ cells on the first day of apheresis","dispersionType":"Full Range","groups":[{"description":"GCSF + Placebo Patients in this group will receive GCSF 10 ug/kg s.c. daily, beginning 4 days prior to the 1st apheresis \\[days -4, -3, -2, -1\\] and continued on daily GCSF for a total of 4 apheresis or until ≥ 5 x 10\\^6 CD34+ cells/kg are collected. They will also receive oral placebo for 5 days on days -6 through -2. Patients will undergo apheresis for 300 minutes to achieve approximately 3 to 4 whole blood volumes processed. This is a standard institutional protocol for autologous HSPC collection at the MGH.\n\nGCSF\n\nPlacebo","id":"OG000","title":"A. GCSF + Placebo"},{"description":"B. GCSF + meloxicam:\n\nPatients in this group will be treated with meloxicam and GCSF in an approximate two-day staggered dose schedule as described in our preclinical studies. Meloxicam will be given orally at a dose of 15 mg/day for 5 days (days -6 through -2). GCSF at 10 ug/kg/day subcutaneously will be started on day -4 and continued daily for a total of 4 apheresis or until ≥ 5 x 10\\^6 CD34+ cells/kg are collected.\n\nGCSF\n\nmeloxicam","id":"OG001","title":"B. GCSF + Meloxicam"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"3 days after starting treatment (or 9 days for multiple myeloma patients that received cyclophosphamide)","title":"Numbers of Circulating CD34+ Cells on the First Day of Apheresis","type":"PRIMARY","unitOfMeasure":"Cells per microliter"}